Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

Abstract

To determine whether the risk of adverse cardiovascular (CV) outcomes associated with diabetes differs in patients with low and preserved ejection fraction (EF) heart failure (HF). We analysed outcomes in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme which randomized 7599 patients with symptomatic HF and a broad range of EF. The prevalence of diabetes was 28.3% in patients with preserved EF (>40%) and 28.5% in those with low EF (≤40%). Diabetes was associated with a greater relative risk of CV death or HF hospitalization in patients with preserved EF [hazard ratio (HR) 2.0 (1.70–2.36)] than in patients with low EF [HR 1.60 (1.44–1.77); interaction test P = 0.0009]. For all-cause mortality, the risk conferred by diabetes was similar in both low and preserved EF groups. The effect of candesartan in reducing CV morbidity and mortality outcomes was not modified by having diabetes at baseline (P = 0.09 test for interaction). Diabetes was an independent predictor of CV morbidity and mortality in patients with HF, regardless of EF. The relative risk of CV death or HF hospitalization conferred by diabetes was significantly greater in patients with preserved when compared with those with low EF HF.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehn153

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 21 references

Cited by

See all 694

Metadata

Authors
MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., Pfeffer, M. A., McMurray, J. J. V., & and for the CHARM Investigators
Affiliations
  • Glasgow Royal Infirmary (GB)
  • University of Glasgow (GB)
  • AstraZeneca (United States) (US)
  • Cleveland Clinic (US)
  • Brigham and Women's Hospital (US)
  • Duke University (US)
  • University of Gothenburg (SE)
  • Population Health Research Institute (CA)
Corresponding author
McMurray, J. J.V.
Venue
European Heart Journal
Published
2008-01-18
Volume
29
Issue
11
Pages
1377-1385
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W1821804635
Cited by
694
References
21
Citations by year
2026: 15 · 2025: 42 · 2024: 61 · 2023: 52 · 2022: 49 · 2021: 86 · 2020: 74 · 2019: 68 · 2018: 41 · 2017: 54 · 2016: 31 · 2015: 22 · 2014: 21 · 2013: 10 · 2012: 13
FWCI
13.10
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
diabetes mellitus, heart failure, ejection fraction, preserved ejection fraction, reduced ejection fraction, candesartan, cardiovascular mortality, heart failure hospitalization, all-cause mortality, cardiovascular morbidity, CHARM trial, ACE inhibitors
MeSH terms
Aged, Benzimidazoles, Biphenyl Compounds, Diabetic Angiopathies, Epidemiologic Methods, Female, Heart Failure, Humans, Male, Prognosis, Stroke Volume, Tetrazoles, Treatment Outcome, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. https://app.cochat.ai/papers/10.1093/eurheartj/ehn153
The paper
MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., Pfeffer, M. A., McMurray, J. J. V., & and for the CHARM Investigators. (2008). Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal. https://doi.org/10.1093/eurheartj/ehn153

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.